Table 1.
Patient demographics and diagnosis and details of lipoprotein apheresis treatment.
| Patient (N = 11) |
Age, years | Male (n = 10) Female (n = 1) |
Treatment frequency | Processed volume, mL | DALI configuration | Diagnosis | CAD |
|---|---|---|---|---|---|---|---|
| 1 | 47 | Male | Weekly | 10000 | 1250 | HyperLp(a) | AWA |
| 2 | 62 | Male | Weekly | 10000 | 1250 | HyperLp(a) | Yes |
| 3 | 52 | Male | Biweekly | 10000 | 1250 | HyperLp(a) | Yes |
| 4 | 43 | Male | Biweekly | 10000 | 1250 | HyperLp(a) | Yes |
| 5 | 49 | Male | Biweekly | 10000 | 1000 | HyperLp(a) | Yes |
| 6 | 52 | Female | Biweekly | 10000 | 1250 | HyperLp(a) | Yes |
| 7 | 50 | Male | Weekly | 10000 | 1250 | HyperLp(a) | Yes |
| 8 | 73 | Male | Biweekly | 10000 | 1000 | HyperLp(a) | Yes |
| 9 | 51 | Male | Weekly | 10000 | 1250 | HyperLp(a) | Yes |
| 10 | 63 | Male | Weekly | 10000 | 1250 | HyperLp(a) | Yes |
| 11 | 66 | Male | Weekly | 10000 | 1250 | HyperLp(a) | Yes |
DALI, Direct Adsorption of Lipids; HyperLp(a), hyperLp(a)lipoproteinemia; CAD, coronary artery disease; AWA, arterial wall atherosclerosis assessed by angiography but no CAD.